News|Articles|September 25, 2023
Changing regulatory environment for nitrosamine impurities
Author(s)SGS Health Science
This SGS Health Science whitepaper uncovers the changing regulatory environment, and the challenges posed by the detection of nitrosamine impurities in drug products.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5